secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-03-17T23:59:59+00:00
Accession:  0001193125-23-073905
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks terminates collaboration with Daiichi Sankyo, forfeiting up to $149.9M in milestones
--------------------------------------------------------------------------------

- Collaboration Agreement terminated March 17, 2023; Zymeworks had received $6.5M total upfront and option payments.
- Zymeworks forfeits potential development milestones of up to $63.4M and commercial milestones of up to $80.0M.
- Zymeworks retains non-exclusive, royalty-bearing rights to develop products using Daiichi's immune-oncology antibodies.
- Daiichi receives non-exclusive, royalty-free license to Zymeworks IP for up to 18 months for additional research.
- Agreement termination does not relieve accrued obligations; no termination fees disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523073905/0001193125-23-073905-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523073905/d486987d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-073905

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer